BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla ...
FORECAST.ETS applies an exponential triple smoothing (ETS) algorithm to create forecasts that can include trend and seasonal ...
Jon McManus, Inova’s chief data and AI officer, says that as the number of AI solutions deployed multiply, health systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback